1. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study
- Author
-
Ak, N., Ozkan, B., Yenigun, M. B., Yilmazbayhan, D., Toker, A., Ferhatoglu, F., Yasar, A., Sak, S. D., Tanju, S., Dilege, S., Erus, S., Bulutay, P., Firat, P., Mandel, N. M., Kilickap, S., Onder, S., Dikmen, E., Alan, O., Yumuk, P. F., Bozkurtlar, E., Lacin, T., Yildizeli, B., Ozturk, A., Kocaturk, C., Karapinar, K., Urer, N., Oyan, B., Aydiner, A., Demirkazik, A., and Yesim Eralp
- Subjects
Adult ,Aged, 80 and over ,Male ,Lung Neoplasms ,Adolescent ,Turkey ,Middle Aged ,Tumor Burden ,Young Adult ,Chemotherapy, Adjuvant ,Carcinoma, Non-Small-Cell Lung ,Humans ,Female ,Aged ,Neoplasm Staging ,Retrospective Studies - Abstract
The benefit of adjuvant chemotherapy for tumors smaller than 4 cm is not clear. We aimed to evaluate the prognostic impact of adjuvant platin-based chemotherapy in high-risk stage I patients with non-small cell lung cancer (NSCLC).This cooperative group study included 232 NSCLC patients who underwent curative surgery for stage I disease with tumor size 2-4 cm. Re ults: Median age at presentation was 63 years (range 18-90). The mean tumor size was 29.6 ± 7.3 mm. The frequency of patients with specified risk factors were: visceral pleural effusion (VPI): n: 82 (36.6%); lymphovascular invasion (LVI): n: 86 (39.1%); Grade 3: n: 48 (32.7%); Solid micropapillary pattern (SMP): n: 70 (48.3%). Adjuvant platin-based chemotherapy was administered to 51 patients. During a median follow-up period of 50.5 months 68 patients (29.3%) developed recurrence, 54 (23.3%) died from any cause and 38 (16.4%) of them died of lung cancer. Patients who received chemotherapy compared with the non-chemotherapy group had a longer 5-years relapse-free survival (RFS) (84.5 vs 61.1%). Also on multivariate analysis, adjuvant chemotherapy was a significant independent prognostic factor for RFS.Adjuvant platin-based chemotherapy should be considered for patients with small tumors with adverse risk factors. Key words: adjuvant chemotherapy, lung cancer, oncology, lymphovascular invasion, solid-micropapillary pattern, platinum-based therapy.
- Published
- 2021